BAFNA PHARMACEUTICALS LTD. - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Download 
|
< Back |
| 05 Aug 2021 | |
| Bafna Pharma Posts INR 208.70 Lakhs Profit in Q1<BR> Company posts good profits on the back of some great export deliveries.<BR> Pandemic has brought the team even closer.<BR> Chennai, August 5, 2021: Chennai based Bafna Pharmaceuticals Limited posted a topline growth of Rs. 2142.87 Lakhs, a growth of over 26% in the First Quarter of FY 2021 - 2022 against Rs. 1687.80 Lakhs in the corresponding period last year. The profits for the period surged to Rs. 208.70 Lakhs as against Rs. 181.16 Lakhs last year; registering a robust growth of 15%. Bafna Pharma has been listed in BSE and NSE. <BR> This robust growth has come despite the raging pandemic for most part of the quarter.<BR> Says Head of Business Development, Navin Bafna, 'this growth in numbers has been due to the collective efforts of the team who worked incredibly hard to achieve it inspite of the uncertainty and personal losses. Our business model and the government's vision of giving priority to Pharma products' exports.<BR> | |
| View all announcements for BAFNA PHARMACEUTICALS LTD. | Source: BSE India |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback